BioVie Announces Approval From U.S. Army Medical Research and Development Command, Office of Human Research Oversight For Its Plan To Evaluate Bezisterim In Long Covid, Co. Receives $13.1M In Funding
Portfolio Pulse from Benzinga Newsdesk
BioVie has received approval from the U.S. Army Medical Research and Development Command to evaluate its drug Bezisterim for Long Covid. The company also secured $13.1 million in funding.
September 16, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie received approval to evaluate Bezisterim for Long Covid and $13.1M in funding, potentially boosting its research capabilities and market position.
The approval from a significant entity like the U.S. Army Medical Research and Development Command enhances BioVie's credibility and potential market impact. The $13.1M funding supports further research and development, likely leading to positive investor sentiment and a short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100